The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices

Vertex Pharmaceuticals' (NASDAQ: VRTX) stock price is up, but its Casgevy sales partner, CRISPR Therapeutics (NASDAQ: CRSP), is the real buy for long-term investors. Shares of Vertex, a biotech based in Boston, popped last week after it reported its fourth-quarter results, which included higher 2025 sales for Casgevy, a gene-editing therapy for two genetic blood disorders: sickle cell disease and beta thalassemia. Vertex is already profitable, and makes most of its revenues by selling the only approved dru ...